19,166 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Purchased by Sapient Capital LLC

Sapient Capital LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,166 shares of the company's stock, valued at approximately $10,638,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Panagora Asset Management Inc. lifted its stake in shares of IDEXX Laboratories by 50.3% in the 1st quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company's stock valued at $1,768,000 after purchasing an additional 1,081 shares during the period. Raymond James Trust N.A. increased its holdings in IDEXX Laboratories by 26.8% in the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company's stock worth $888,000 after purchasing an additional 343 shares in the last quarter. Cetera Investment Advisers lifted its stake in IDEXX Laboratories by 77.1% in the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company's stock valued at $2,010,000 after buying an additional 1,600 shares during the period. Moors & Cabot Inc. boosted its holdings in shares of IDEXX Laboratories by 3.0% during the 1st quarter. Moors & Cabot Inc. now owns 1,757 shares of the company's stock worth $961,000 after buying an additional 52 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in shares of IDEXX Laboratories by 15.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company's stock worth $543,000 after buying an additional 134 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.2 %

Shares of IDEXX Laboratories stock traded down $1.04 on Thursday, hitting $503.10. The company had a trading volume of 381,797 shares, compared to its average volume of 422,198. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a 50 day moving average of $547.97 and a 200-day moving average of $506.75. The stock has a market capitalization of $41.78 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 2.82 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.05 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the company's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares of the company's stock, valued at approximately $3,851,815.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP George Fennell sold 8,198 shares of the firm's stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares of the company's stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock valued at $24,871,960 over the last ninety days. Corporate insiders own 2.18% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on IDXX shares. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Wednesday, December 20th. Piper Sandler downgraded IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. The Goldman Sachs Group boosted their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an "overweight" rating in a report on Tuesday, February 6th. Finally, William Blair reissued an "outperform" rating on shares of IDEXX Laboratories in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $591.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.